Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has 87 patents on the derivation of angiogenic cell precursors (ACP-01), neuronal cell precursors (NCP-01) and cardiomyocyte cell precursors (CCP-01) fro... Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has 87 patents on the derivation of angiogenic cell precursors (ACP-01), neuronal cell precursors (NCP-01) and cardiomyocyte cell precursors (CCP-01) from a synergetic cell population that is sourced from the patient's blood. The Company is selling exempt compassionate treatments to individuals afflicted with critical limb ischemia, for example, and conducting clinical trials to commercialize its lead product, ACP-01, for the treatment of critical limb ischemia and peripheral arterial disease, and heart disease (ischemic cardiomyopathy, dilated cardiomyopathy). Show more
HEMOSTEMIX ANNOUNCES CLOSING OF UNIT PRIVATE PLACEMENT May 10, 2021, Calgary, Alberta -- InvestorsHub NewsWire -- Hemostemix Inc...
Hemostemix Announces Completion of Phase II Clinical Trial Subject Follow Up & HMTXF Up-list Calgary, Alberta, April 23, 2021-- InvestorsHub NewsWire -- Hemostemix Inc. ("Hemostemix" or the...
Hemostemix Announces a $2,500,000 Lead Order and its Clinical Trial and Litigation Updates Calgary, Alberta, April 12, 2021-- InvestorsHub NewHemostemix Inc...
Hemostemix Annonces it is Trading on the Frankfurt Stock Exchange and it has Retained HE Capital Markets LTD. Calgary, Alberta, April 8, 2021 -- InvestorsHub NewsWire...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0005 | -0.884955752212 | 0.0565 | 0.0565 | 0.056 | 5260 | 0.05602139 | CS |
| 4 | -0.01305 | -18.8993482983 | 0.06905 | 0.0725 | 0.0549 | 6715 | 0.06635621 | CS |
| 12 | 0.005 | 9.80392156863 | 0.051 | 0.078 | 0.0323 | 31320 | 0.0548345 | CS |
| 26 | 0.026 | 86.6666666667 | 0.03 | 0.079 | 0.024 | 22072 | 0.0503626 | CS |
| 52 | 0.0054 | 10.6719367589 | 0.0506 | 0.079 | 0.024 | 17780 | 0.05019133 | CS |
| 156 | -0.0711 | -55.9402045633 | 0.1271 | 0.3279 | 0.024 | 20785 | 0.13663361 | CS |
| 260 | 0.046 | 460 | 0.01 | 0.4372 | 0.0049 | 34617 | 0.0823538 | CS |
| Symbole | Prix | Vol. |
|---|---|---|
| SPRVSupurva Healthcare Group Inc (PK) | US$ 0,0001 (-50,00%) | 163,23M |
| ASIIAccredited Solutions Inc (PK) | US$ 0,0006 (33,33%) | 152,19M |
| CBGLCannabis Global Inc (PK) | US$ 0,0001 (100,00%) | 149,39M |
| GRLFGreen Leaf Innovations Inc (PK) | US$ 0,0001 (0,00%) | 118,61M |
| ABQQAB International Group Corporation (PK) | US$ 0,0011 (10,00%) | 103,11M |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Premium
